Amgen Inc. (AMGN)
Countdown to Amgen (AMGN) Q4 Earnings: Wall Street Forecasts for Key Metrics
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Amgen Set to Report Q4 Earnings: What Investors Should Know
AMGN stock is in focus ahead of Q4 earnings, with biosimilar pressure and newer drug growth shaping expectations for the quarter.
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (AMGN) Laps the Stock Market: Here's Why
In the most recent trading session, Amgen (AMGN) closed at $349.69, indicating a +1.43% shift from the previous trading day.
Here's Why Amgen (AMGN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential
Amgen Inc. is rated a Buy, driven by robust pipeline prospects and the transformative potential of its obesity drug candidate MariTide. Recent AMGN performance includes 12% revenue growth in Q3 2025, upwardly revised 2025 guidance, and healthy operating margins near 30%. Patent expiries will pressure legacy products, but new launches and biosimilars are expected to offset declines, with pipeline assets potentially accelerating growth post-2026.
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
In the latest trading session, Amgen (AMGN) closed at $328.97, marking a +1.44% move from the previous day.
Ro partners with Amgen to study barriers to obesity care, GLP-1 access
U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to examine challenges patients and providers face in accessing obesity treatments, including GLP-1 therapies.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amgen to announce data on obesity drug MariTide at healthcare conference
Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on Monday to unveil results from a mid-stage trial extension designed to show if the medication helps people maintain weight loss.
